ABBVIE
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3000
- Registration Number
- NCT06603558
- Locations
- 🇰🇷
Hallym University Dongtan Sacred Heart Hospital /ID# 273581, Hwaseong, Gyeonggido, Korea, Republic of
🇰🇷Yonsei University Health System Severance Hospital /ID# 272639, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷Seoul National University Hospital /ID# 271892, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Expanded Access to Fosigotifator
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06594016
A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088
- Conditions
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT06579300
- Locations
- 🇺🇸
Acpru /Id# 270552, Grayslake, Illinois, United States
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
- Conditions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 280
- Registration Number
- NCT06581042
- Locations
- 🇧🇪
Imelda Ziekenhuis /ID# 268631, Bonheiden, Antwerpen, Belgium
🇧🇪CHU de Liège /ID# 267209, Liège, Liege, Belgium
🇧🇪UZ Gent /ID# 268630, Gent, Oost-Vlaanderen, Belgium
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 783
- Registration Number
- NCT06575192
- Locations
- 🇺🇸
Washington University School of Medicine - St. Louis /ID# 264029, Saint Louis, Missouri, United States
🇺🇸University of Nevada - Main Campus /ID# 264017, Las Vegas, Nevada, United States
🇺🇸Rutgers New Jersey Medical School - Newark /ID# 264187, Newark, New Jersey, United States
A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 231
- Registration Number
- NCT06571266
- Locations
- 🇺🇸
Cenexel Act /ID# 270310, Anaheim, California, United States
🇺🇸Collaborative Neuroscience Research CNS /ID# 270286, Los Alamitos, California, United States
🇺🇸Acpru /Id# 270152, Grayslake, Illinois, United States
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT06568939
A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
- Conditions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT06548568
- Locations
- 🇨🇳
Qingdao Eye Hospital of Shandong First Medical University /ID# 268173, Qingdao, Shandong, China
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 500
- Registration Number
- NCT06548542
- Locations
- 🇵🇹
2CA-Braga, Hospital de Braga /ID# 265894, Braga, Portugal
🇵🇹Unidade Local de Saude de Coimbra, EPE /ID# 267240, Coimbra, Portugal
🇵🇹Unidade Local de Saude de Lisboa Ocidental, EPE /ID# 267242, Lisboa, Portugal
A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 135
- Registration Number
- NCT06547125
- Locations
- 🇨🇳
China-Japan Friendship Hospital /ID# 260959, Beijing, Beijing, China
🇨🇳Huashan Hospital, Fudan University /ID# 261582, Shanghai, Shanghai, China
🇨🇳Peking University First Hospital /ID# 260957, Xicheng District, Beijing, China